

NCT02141061 Raw comparison:

Summary:
CHIA has 21 criteria while your personal folder has 24 criteria
Total found criteria: 21/21
Total not Found: 0/21
Total Extra: 3
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Speak read and understand English or Spanish and   │ Speak read and understand English or Spanish and   │
│ is willing and able to provide written informed    │ is willing and able to provide written informed    │
│ consent on an IRB-approved form prior to the       │ consent on an IRB-approved form prior to the       │
│ initiation of any study procedures                 │ initiation of any study procedures                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Healthy premenopausal female age 18-47             │ Healthy premenopausal female age 18-47             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of menstrual events that occur in regular  │ History of menstrual events that occur in regular  │
│ cycles                                             │ cycles                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Agreement not to attempt to become pregnant        │ Agreement not to attempt to become pregnant        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Agrees to use double-barrier contraception during  │ Agrees to use double-barrier contraception during  │
│ the study and for 30 days after discontinuation of │ the study and for 30 days after discontinuation of │
│ study medication Acceptable double-barrier methods │ study medication Acceptable double-barrier methods │
│ are male condom with spermicide male condom with   │ are male condom with spermicide male condom with   │
│ diaphragm diaphragm containing spermicide plus     │ diaphragm diaphragm containing spermicide plus     │
│ additional intra-vaginal spermicide                │ additional intra-vaginal spermicide                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Has a negative pregnancy test at the Screening     │ Has a negative pregnancy test at the Screening     │
│ visit An exception for the pregnancy test          │ visit An exception for the pregnancy test          │
│ requirement will be granted for subjects reporting │ requirement will be granted for subjects reporting │
│ surgical sterilization in medical history          │ surgical sterilization in medical history          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Normal laboratory values or clinically             │ Normal laboratory values or clinically             │
│ insignificant findings at screening as determined  │ insignificant findings at screening as determined  │
│ by the Investigator                                │ by the Investigator                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is willing to remain in the clinic         │ Subject is willing to remain in the clinic         │
│ overnight for PK assessment on Days 0 and 8        │ overnight for PK assessment on Days 0 and 8        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ability to complete the study procedures in        │ Ability to complete the study procedures in        │
│ compliance with the protocol                       │ compliance with the protocol                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is a post-menopausal woman defined as      │ Subject is a post-menopausal woman defined as      │
│ either six (6) months or more (immediately prior   │ either six (6) months or more (immediately prior   │
│ to screening visit) without a menstrual period or  │ to screening visit) without a menstrual period or  │
│ prior hysterectomy and/or oophorectomy             │ prior hysterectomy and/or oophorectomy             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is pregnant or lactating or is attempting  │ Subject is pregnant or lactating or is attempting  │
│ or expecting to become pregnant during the study   │ or expecting to become pregnant during the study   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women with abnormally high liver enzymes or liver  │ Women with abnormally high liver enzymes or liver  │
│ disease (ALT or AST exceeding 2 0 x ULN AND total  │ disease (ALT or AST exceeding 2 0 x ULN AND total  │
│ bilirubin exceeding 1 5 x ULN at screening and     │ bilirubin exceeding 1 5 x ULN at screening and     │
│ confirmed on repeat)                               │ confirmed on repeat)                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Received an investigational drug in the 30 days    │ Received an investigational drug in the 30 days    │
│ prior to the screening for this study              │ prior to the screening for this study              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women with a history of PCOS                       │ Women with a history of PCOS                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concurrent use of any testosterone progestin       │ Concurrent use of any testosterone progestin       │
│ androgen estrogen anabolic steroids DHEA or        │ androgen estrogen anabolic steroids DHEA or        │
│ hormonal products for at least 2 weeks prior to    │ hormonal products for at least 2 weeks prior to    │
│ screening and during the study                     │ screening and during the study                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of oral contraceptives in the preceding 2      │ Use of oral contraceptives in the preceding 2      │
│ weeks Use of Depo-Provera® in the preceding 10     │ weeks Use of Depo-Provera® in the preceding 10     │
│ months                                             │ months                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Has an IUD in place                                │ Has an IUD in place                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women currently using narcotics                    │ Women currently using narcotics                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women currently taking spironolactone              │ Women currently taking spironolactone              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Infectious disease screen is positive for HIV or   │ Infectious disease screen is positive for HIV or   │
│ Hepatitis A B or C                                 │ Hepatitis A B or C                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically significant abnormal findings on        │ Clinically significant abnormal findings on        │
│ screening examination or any condition which in    │ screening examination or any condition which in    │
│ the opinion of the investigator would interfere    │ the opinion of the investigator would interfere    │
│ with the participant's ability to comply with the  │ with the participant's ability to comply with the  │
│ study instructions or endanger the participant if  │ study instructions or endanger the participant if  │
│ she took part in the study                         │ she took part in the study                         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have maximum age of 47 Years │
├───────────────────────────────────┤
│ Must be FEMALE                    │
├───────────────────────────────────┤
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛